The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $764,366 in first-year total cost, median $253,625.
Most frequent study sections
- Special Emphasis Panel[ZHD1 DRG-H (91)]3
Most frequent institutions
- UNIVERSITY OF KANSAS MEDICAL CENTER2
- COLUMBIA UNIVERSITY HEALTH SCIENCES1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2014 | Retinoid Receptor Antagonists as Novel Male Contraceptives2U01HD060479-06 | WOLGEMUTH, DEBRA J. | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $275,200 | ZHD1 |
| 2014 | Inhibitors of Na,K-ATPase alpha4 as male contraceptives1U01HD080423-01 | BLANCO, V GUSTAVO | UNIVERSITY OF KANSAS MEDICAL CENTER, KS | $253,625 | ZHD1 |
| 2014 | Cell-cycle regulatory kinases as targets for male contraceptive drug development1U01HD080431-01 | TASH, JOSEPH S | UNIVERSITY OF KANSAS MEDICAL CENTER, KS | $235,541 | ZHD1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.